NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $5.45 +0.07 (+1.30%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$5.60 +0.15 (+2.73%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Abeona Therapeutics Stock (NASDAQ:ABEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$5.24▼$5.4850-Day Range$4.23▼$6.0152-Week Range$4.00▼$7.54Volume1.16 million shsAverage Volume981,006 shsMarket Capitalization$310.60 millionP/E Ratio5.62Dividend YieldN/APrice Target$19.00Consensus RatingHold Company Overview Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need. The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa. These candidates have advanced through early‐stage trials, offering initial proof of concept in delivering corrective genetic material to affected tissues. Abeona is also exploring innovative oncology cell therapy approaches that apply its gene delivery expertise to tumor targeting. Abeona supports its pipeline with cGMP manufacturing facilities in Cleveland and Cambridge, complemented by a research presence in the Texas Medical Center to scale vector production and process development. The company has forged strategic collaborations to streamline clinical supply and broaden patient access, reflecting its commitment to advancing transformative medicines globally. Under the guidance of its executive leadership, Abeona continues to engage with regulatory authorities and expand clinical trial initiatives across North America and Europe.AI Generated. May Contain Errors. Read More Abeona Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreABEO MarketRank™: Abeona Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 238th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingAbeona Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAbeona Therapeutics has a consensus price target of $19.00, representing about 248.6% upside from its current price of $5.45.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is 5.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is 5.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.50.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Abeona Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.18% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 16.41, which indicates bearish sentiment.Change versus previous monthShort interest in Abeona Therapeutics has recently decreased by 0.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. News and Social Media4.6 / 5News Sentiment1.32 News SentimentAbeona Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Abeona Therapeutics this week, compared to 5 articles on an average week.Search Interest14 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows1 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $891,246.00 in company stock.Percentage Held by Insiders7.10% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABEO Stock News HeadlinesAbeona Therapeutics (NASDAQ:ABEO) CEO Sells $132,644.04 in Stock 1 minute ago | insidertrades.comAbeona Advances ABO-701 T-Cell Therapy Toward INDJune 4, 2026 | tipranks.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 10 at 1:00 AM | Behind the Markets (Ad)Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comAbeona Therapeutics (NASDAQ:ABEO) Rating Increased to Sell at Wall Street ZenJune 1, 2026 | americanbankingnews.comMark Alvino Sells 6,500 Shares of Abeona Therapeutics (NASDAQ:ABEO) StockMay 23, 2026 | insidertrades.comInsider Selling: Abeona Therapeutics (NASDAQ:ABEO) Director Sells 26,143 Shares of StockMay 16, 2026 | insidertrades.comAbeona Therapeutics (NASDAQ:ABEO) Insider Sells $33,066.08 in StockMay 12, 2026 | insidertrades.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.27 at the beginning of 2026. Since then, ABEO stock has increased by 3.4% and is now trading at $5.45. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc. (NASDAQ:ABEO) released its quarterly earnings results on Wednesday, May, 13th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.03. The biopharmaceutical company had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million. Read the conference call transcript. When did Abeona Therapeutics' stock split? Shares of Abeona Therapeutics reverse split before market open on Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Abeona Therapeutics' major shareholders? Top institutional investors of Abeona Therapeutics include AIGH Capital Management LLC (5.45%), Simplify Asset Management Inc. (0.89%), Bank of America Corp DE (0.69%) and Sei Investments Co. (0.30%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Madhav Vasanthavada, Leila Alland, Faith L Charles, Christine Berni Silverstein, Michael Amoroso, Mark Alvino and Eric Crombez. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE). Company Calendar Last Earnings5/13/2026Today6/09/2026AGM 20266/12/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ABEO's financial health is in the Red zone, according to TradeSmith. ABEO has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101Employees90Year Founded2013Price Target and Rating Average Price Target for Abeona Therapeutics$19.00 High Price Target$20.00 Low Price Target$17.00 Potential Upside/Downside+248.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.97 Trailing P/E Ratio5.62 Forward P/E RatioN/A P/E GrowthN/ANet Income$71.18 million Net MarginsN/A Pretax Margin455.56% Return on Equity-53.98% Return on Assets-38.52% Debt Debt-to-Equity Ratio0.03 Current Ratio5.89 Quick Ratio5.70 Sales & Book Value Annual Sales$5.82 million Price / Sales53.37 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book1.85Miscellaneous Outstanding Shares56,990,000Free Float52,948,000Market Cap$310.60 million OptionableOptionable Beta1.35 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ABEO) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABEO Stock Alerts